VTV Therapeutics - Class A (VTVT) closed at $21.74 on November 5, 2026, down 9.5% from the previous close, on volume of 17,774 shares (30-day average 27,550).
Data as of November 5, 2026.
vTv Therapeutics GAAP EPS of -$0.94 beats by $0.15
Seeking Alpha News (Thu, 5-Nov 5:50 PM ET)
vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
Globe Newswire (Thu, 15-Oct 3:30 AM ET)
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
Globe Newswire (Sat, 10-Oct 8:00 AM ET)
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
Globe Newswire (Wed, 7-Oct 4:01 PM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 15-Sep 4:05 PM ET)
vTv Therapeutics to Participate in September Investor Conferences
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
VTV Therapeutics - Class A trades on the NASDAQ stock market under the symbol VTVT.
As of November 5, 2026, VTVT stock price declined to $21.74 with 17,774 million shares trading.
VTVT has a beta of -0.45, meaning it tends to be less sensitive to market movements. VTVT has a correlation of 0.01 to the broad based SPY ETF.
VTVT has a market cap of $85.96 million. This is considered a Micro Cap stock.
Last quarter VTV Therapeutics - Class A reported $0 in Revenue and -$1.05 earnings per share. This fell short of revenue expectation by $-320,000 and missed earnings estimates by -$.11.
In the last 3 years, VTVT traded as high as $44.00 and as low as $7.38.
The top ETF exchange traded funds that VTVT belongs to (by Net Assets): VTI, VXF, IWC, QQQS, AVSC.
VTVT has underperformed the market in the last year with a price return of -10.3% while the SPY ETF gained +9.3%. VTVT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.8% and -20.0%, respectively, while the SPY returned -4.5% and -4.1%, respectively.
VTVT support price is $22.69 and resistance is $25.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTVT shares will trade within this expected range on the day.
